Literature DB >> 8320556

QSAR and conformational analysis of the antiinflammatory agent amfenac and analogues.

J Ruiz1, M López, J Milà, E Lozoya, J J Lozano, R Pouplana.   

Abstract

The new nonsteroidal antiinflammatory drug (NSAID) arylacetic amfenac (2-amino-3-benzoylphenylacetic acid) and 19 substituted derivatives were studied in order to correlate the biological activities with the structure-related parameters. The geometry of amfenac in neutral and anionic form was totally optimized, starting from standard geometries and crystallographic data, using semiempirical AM1 and MNDO quantum-mechanical methods. Conformational analysis shows the existence of a rigid structure for rotations of the acetic acid chain (alpha degrees) and the central carbonyl group (gamma degrees) around the bonds with the phenylamine ring, whereas the carboxyl group (beta degrees) and the phenyl ring of the benzoyl group (delta degrees) can rotate almost freely. Electrostatic potential maps were analyzed and showed that the electrostatic orientation effect seems to make an important contribution to the binding of the active compounds to prostaglandin synthase. An electrostatic orientation model of the binding site is proposed. The frontier orbital charge distribution was also described for each compound. On the other hand, steric, electronic and hydrophobic (log P) parameters were calculated and QSAR analysis showed that the most significant parameter for the antiinflammatory activity was the pi-electron density of the HOMO orbital in the second aromatic ring. These results suggest a possible electronic charge transfer between the aromatic fragments and the receptor.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8320556     DOI: 10.1007/bf00126444

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  20 in total

1.  AHR-5850: a potent anti-inflammatory compound.

Authors:  L F Sancilio; D L Reese; S Cheung; R S Alphin
Journal:  Agents Actions       Date:  1977-03

2.  Prostaglandin endoperoxide synthase contains an EGF-like domain.

Authors:  H Toh
Journal:  FEBS Lett       Date:  1989-12-04       Impact factor: 4.124

3.  Antiinflammatory agents. 4. Syntheses and biological evaluation of potential prodrugs of 2-amino-3-benzoylbenzeneacetic acid and 2-amino-3-(4-chlorobenzoyl)benzeneacetic acid.

Authors:  D A Walsh; H W Moran; D A Shamblee; W J Welstead; J C Nolan; L F Sancilio; G Graff
Journal:  J Med Chem       Date:  1990-08       Impact factor: 7.446

4.  Topography of prostaglandin H synthase. Antiinflammatory agents and the protease-sensitive arginine 253 region.

Authors:  R J Kulmacz
Journal:  J Biol Chem       Date:  1989-08-25       Impact factor: 5.157

5.  Analgesic action of amfenac Na, a non-steroidal anti-inflammatory agent.

Authors:  T Hiranuma; S Kato; M Hachisu
Journal:  J Pharmacobiodyn       Date:  1988-09

6.  Antiinflammatory agents. 1. Synthesis and antiinflammatory activity of 2-amino-3-benzoylphenylacetic acid.

Authors:  W J Welstead; H W Moran; H F Stauffer; L B Turnbull; L F Sancilio
Journal:  J Med Chem       Date:  1979-09       Impact factor: 7.446

Review 7.  Prostaglandin and thromboxane biosynthesis.

Authors:  W L Smith; L J Marnett; D L DeWitt
Journal:  Pharmacol Ther       Date:  1991       Impact factor: 12.310

8.  Conformational analysis of some alpha-phenylpropionic acids with anti-inflammatory activity.

Authors:  Y G Smeyers; S Cuéllare-Rodriguez; E Galvez-Ruano; M S Arias-Pérez
Journal:  J Pharm Sci       Date:  1985-01       Impact factor: 3.534

9.  A model for the prostaglandin synthetase cyclooxygenation site and its inhibition by antiinflammatory arylacetic acids.

Authors:  P Gund; T Y Shen
Journal:  J Med Chem       Date:  1977-09       Impact factor: 7.446

10.  Synthesis and antiinflammatory and analgesic activity of 5-aroyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acids and related compounds.

Authors:  J M Muchowski; S H Unger; J Ackrell; P Cheung; G F Cooper; J Cook; P Gallegra; O Halpern; R Koehler; A F Kluge
Journal:  J Med Chem       Date:  1985-08       Impact factor: 7.446

View more
  14 in total

Review 1.  Bromfenac Ophthalmic Solution 0.07%: A Review of Its Use After Cataract Surgery.

Authors:  Sheridan M Hoy
Journal:  Clin Drug Investig       Date:  2015-08       Impact factor: 2.859

2.  Bromfenac ophthalmic solution 0.09 %: human aqueous humor concentration detected by high-performance liquid chromatography.

Authors:  Angelo Macrì; Aldo Vagge; Annalisa Salis; Carmen Fucile; Valeria Marini; Antonietta Martelli; Sebastiano Giuffrida; Michele Iester; Gianluca Damonte; Francesca Mattioli
Journal:  Int Ophthalmol       Date:  2016-06-20       Impact factor: 2.031

3.  The structural and electronical factors that contribute affinity for the time-dependent inhibition of PGHS-1 by indomethacin, diclofenac and fenamates.

Authors:  R Pouplana; C Pérez; J Sánchez; J J Lozano; P Puig-Parellada
Journal:  J Comput Aided Mol Des       Date:  1999-05       Impact factor: 3.686

4.  Topical ophthalmic NSAIDs: a discussion with focus on nepafenac ophthalmic suspension.

Authors:  Bruce I Gaynes; Anne Onyekwuluje
Journal:  Clin Ophthalmol       Date:  2008-06

5.  Structure-based QSAR study on differential inhibition of human prostaglandin endoperoxide H synthase-2 (COX-2) by nonsteroidal anti-inflammatory drugs.

Authors:  R Pouplana; J J Lozano; C Pérez; J Ruiz
Journal:  J Comput Aided Mol Des       Date:  2002-10       Impact factor: 3.686

6.  Evaluation of analgesic efficacy of bromfenac sodium ophthalmic solution 0.09% versus ketorolac tromethamine ophthalmic solution 0.5% following LASEK or Epi-LASIK.

Authors:  Xiao Jing Wang; Sze H Wong; Roshan Givergis; Emil W Chynn
Journal:  Clin Ophthalmol       Date:  2011-10-07

7.  Drug design for ever, from hype to hope.

Authors:  G Seddon; V Lounnas; R McGuire; T van den Bergh; R P Bywater; L Oliveira; G Vriend
Journal:  J Comput Aided Mol Des       Date:  2012-01-18       Impact factor: 3.686

8.  Comparison of a preservative-free nonsteroidal anti-inflammatory drug and preservative-free corticosteroid after uneventful cataract surgery: multicenter, randomized, evaluator-blinded clinical trial.

Authors:  Seonjoo Kim; Byung-Yi Ko; Jae Woong Koh; Eun Chul Kim; Hong Kyun Kim; Young Joo Shin; Jong-Suk Song; Do Hyung Lee; Ji Eun Lee; Hyung Keun Lee; So-Hyang Chung; Hyun Seung Kim
Journal:  J Cataract Refract Surg       Date:  2021-10-08       Impact factor: 3.528

9.  Update on twice-daily bromfenac sodium sesquihydrate to treat postoperative ocular inflammation following cataract extraction.

Authors:  Ester Carreño; Alejandro Portero; David J Galarreta; José M Herreras
Journal:  Clin Ophthalmol       Date:  2012-04-27

10.  The efficacy of bromfenac ophthalmic solution 0.07% dosed once daily in achieving zero-to-trace anterior chamber cell severity following cataract surgery.

Authors:  Steven M Silverstein; Mitchell A Jackson; Damien F Goldberg; Mauricio Muñoz
Journal:  Clin Ophthalmol       Date:  2014-05-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.